Evotec's Credibility Test Comes Down to One Number: the Operating Margin
Published on 09/24/2026 at 17:50 | Editorial boerse-global.de
Evotec shares changed hands at EUR 2.77 in German trading on Thursday, a decline of 1.7% on the day, leaving the Hamburg-based drug discovery specialist 64% below its 52-week high of EUR 7.75. The stock has lost 48% since the start of the year, and the market's mood is one of accumulated disappointment rather than active panic.
What matters now is not the daily tape but whether management can convert a pipeline of promising science into visible cost savings. The company's next scheduled report, on November 5, has become the single most anticipated date on the calendar for shareholders.
A Guidance Cut That Reset Expectations
The operational backdrop was set in the summer, when Evotec slashed its full-year outlook. Revenue for 2026 is now projected at EUR 570 million to EUR 610 million, down from an earlier target of EUR 700 million to EUR 780 million. Adjusted EBITDA is expected to land between a loss of EUR 70 million and a loss of EUR 105 million, compared with an original range of EUR 0 to EUR 40 million.
Management attributed the shortfall primarily to delays in strategic partnerships, which account for roughly 40% of the revenue reduction, compounded by softer demand in Discovery & Pre-clinical Development (D&PD).
The countermeasure is the "Horizon" transformation program, which targets annual cost savings of EUR 75 million by the end of 2027. Between 20% and 30% of that total is meant to be realized during the current year.
Should investors sell immediately? Or is it worth buying Evotec?
Where the Business Is Actually Growing
Beneath the headline weakness, two parts of the group are moving in the right direction. Net sales in D&PD climbed more than 28% year over year in the first half of 2026, even as the segment as a whole faced headwinds. Just – Evotec Biologics, the company's biologics arm, also showed positive momentum, with high capacity utilization and an expanding customer base providing a measure of fundamental stability.
The problem is that margins have not kept pace with that revenue growth. Until improved customer engagement translates into measurable earnings gains, investors are likely to stay on the sidelines. Hitting the reduced targets is now viewed across trading desks as a minimum requirement rather than an aspiration.
Pipeline News Offers the Bull Case
Several developments on the science side argue for patience. Just over a week ago, Evotec began a Phase I clinical trial of JST-018, an antibody program targeting orthopoxviruses for the U.S. Department of Defense — a signal that large public-sector customers retain confidence in the company's platform technology. Roughly three weeks earlier, Evotec signed a research collaboration with Plectonic Biotech, pairing its own BiTco platform with LOGIBODY technology to pursue novel T-cell engagers in solid tumors, underscoring its oncology credentials.
CFO Claire Hinshelwood struck an optimistic tone at an investor conference about a week ago, pointing to business indicators that are moving in the right direction and should eventually feed through to future revenue. Whether those indicators can offset persistent margin pressure will become clearer on November 5.
Dilution and Governance Add to the Drag
Weighing against the bull case is a capital structure that has grown more burdensome. The issuance of new subscription shares that took effect about a week ago lifted the total number of voting rights to 177,909,968, diluting existing holders. Expanding the share base into a weak market signals elevated capital needs and compresses valuation multiples.
There has also been movement in the supervisory board, following Camilla Macapili Languille's departure in August. Should it emerge that July's sharp downgrade of the annual targets was not the end of the revisions, the risk of a further downward spiral grows — particularly if weak order intake in early-stage drug discovery continues to weigh on laboratory utilization and slows the turnaround effort.
The Chart Level That Sets the Tone
For the weeks ahead, the risk profile is clearly defined. As long as the 52-week low of EUR 2.76 is not breached on a sustained basis, the prospect of stabilization and a subsequent technical rebound remains alive. In that scenario, confirmation of an operational turnaround could be enough to draw underinvested market participants back in.
A daily close below that support, by contrast, would likely accelerate selling, with follow-on orders and stop-losses driving the price lower. The quarterly report stands as the next real test of whether the strategy holds — the moment when the market will measure the actual pace of the operational recovery.
Ad
Evotec Stock: New Analysis - 24 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
